Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen

Abstract

declare that they have no conflict of interest.Ethics approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.Informed consent: Informed consent was obtained from all individual participants included in the study.Data availability: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.Code availability: The model code that we developed is provided as an electronic supplementary information, so the model can be copy-pasted by any reader and run directly on Monolix® software with the users' own dataset.

Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai

“…Many anticancer drugs are often combined with irinotecan for the treatment of solid tumors, of which oxaliplatin has been reported to significantly modify the distribution of SN-38; in contrast, coadministration of monoclonal antibody was not a significant covariate for the population pharmacokinetic model of irinotecan, which suggests a pharmacokinetic interaction between platinum and irinotecan. 21 Since both irinotecan and platinum are substrates of ATP-binding cassette (ABC) transporters, ABC polymorphisms or expression may also affect their pharmacokinetics, as well as drugrelated toxicities, mainly including hematologic and gastrointestinal toxicities. [22][23][24][25] On the other hand, organic anion-transporting polypeptide uptake transport was also demonstrated to affect the pharmacokinetics and toxicities of both irinotecan and SN-38, as well as the efficacy and toxic side effects of platinumbased chemotherapy.…”